scholarly journals Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients

2016 ◽  
pp. 93 ◽  
Author(s):  
Shu Okugawa ◽  
Kazuhito Yuhashi ◽  
Yuka Yagihara ◽  
Yoshiki Miasawa ◽  
Tomoaki Sato ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Enzyme Immunoassay ◽  
Glutamate Dehydrogenase ◽  
Clinical Significance ◽  
Clostridium Difficile Associated Diarrhea

scholarly journals Comparison of the Vidas C. difficile GDH Automated Enzyme-Linked Fluorescence Immunoassay (ELFA) with Another Commercial Enzyme Immunoassay (EIA) (Quik Chek-60), Two Selective Media, and a PCR Assay forgluDfor Detection of Clostridium difficile in Fecal Samples

2015 ◽  
Vol 53 (6) ◽  
pp. 1931-1934 ◽  
Author(s):  
K. A. Davies ◽  
C. E. Berry ◽  
K. A. Morris ◽  
R. Smith ◽  
S. Young ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Enzyme Immunoassay ◽  
Glutamate Dehydrogenase ◽  
Fluorescence Immunoassay ◽  
Pcr Assay ◽  
Two Stage ◽  
Fecal Samples ◽  
Content Type ◽  
Selective Media ◽  
Commercial Enzyme Immunoassay

Prevention and management ofClostridium difficileinfection (CDI) can be improved by rapid and reliable diagnostics. The VidasC. difficileglutamate dehydrogenase assay had performance comparable to that of the Quik Chek-60 assay (overall agreement, 95%) and a sensitivity of >93%; thus, it is suitable as the first test in two-stage algorithms for a CDI diagnosis.

scholarly journals Infections caused by Clostridium difficile in cancer patients

2019 ◽  
Vol 17 (6) ◽  
pp. 92-96
Author(s):  
I. A. Klyuchnikova ◽  
I. N. Petukhova ◽  
Z. V. Grigorievskaya ◽  
N. S. Bagirova ◽  
I. V. Tereshchenko ◽  
...  
Keyword(s):  
Risk Factor ◽  
Clostridium Difficile ◽  
Early Detection ◽  
Enzyme Immunoassay ◽  
Cancer Patients ◽  
Early Onset ◽  
Main Risk Factor ◽  
Cephalosporin Antibiotics ◽  
Clostridium Difficile Associated Diarrhea

The purpose of the studywas to determine the role of antibiotics as a risk factor of Clostridium difficile-associated diarrhea in hospitalized cancer patients.Material and Methods. The study included 844 hospitalized cancer patients with diarrhea. The presence of Clostridium difficile toxins A and B in the fecal samples was determined by enzyme immunoassay.Results.Clostridium difficile toxins A and B were detected in 100 cancer patients (42 % men and 58 % women). The incidence of Clostridium difficile-associated diarrhea was higher in women than in men (р<0.02). Patients with hemoblastosis and gastrointestinal tumors were more susceptible to the development of Clostridium difficile associated diarrhea (p<0.02). The use of cephalosporin antibiotics was the main risk factor (р<0.001). In our study, 46 % of the patients took antibiotics.Conclusion.Clostridium difficile was shown to play a significant role in the development of diarrhea in cancer patients, and early detection of Clostridium difficile infection contributes to the early onset of therapy.

Sign in / Sign up

Export Citation Format

Share Document